Humanigen, Inc.: Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly1 Lenzilumab plus SOC resulted

Related Keywords

United Kingdom ,Ken Trbovich ,Adrian Kilcoyne ,Crpabout Lenzilumab ,Twitter ,United Kingdom Health Security Agency ,Nasdaq ,Outcomes Research ,National Health Service England ,National Health Service ,Humanigen Inc ,Facebook ,Chief Medical Officer ,Host Disease ,Kingdom Health Security ,Kingdom Coronavirus ,Retrieved April ,Humanigen ,Nnounces ,Beer ,Eviewed ,Publication ,Emonstrating ,Potential ,Linical ,Economic ,Benefits ,Lenzilumab ,Rom ,Perspective ,